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ABSTRACT
Atrial fibrillation (AF) affects millions of Americans and puts them at increased risk for
ischemic stroke. It is important for providers to recognize AF and know when it is appropriate to
treat patients with anticoagulation. There are several options available for anticoagulation.
Warfarin is the most widely used anticoagulant. Other alternatives to warfarin are new oral
anticoagulants (NOACs) which are increasingly prescribed in recent years. It is vital providers
know the differences between warfarin and NOACs, and what is the most appropriate
anticoagulant to use for their patient with AF. The purpose of this paper is to review the clinical
presentation of AF and compare the use of warfarin versus NOACs for the prevention of
ischemic stroke.
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Use of New Oral Anticoagulants in Preventing Ischemic
Stroke in Patients with Atrial Fibrillation
Background
Atrial fibrillation (AF) is a common disorder many nurse practitioners will encounter in
their practice. Currently, AF in the United States affects over two million people (Mahtani,
Heneghan, & Tai, 2012). It is projected that more than 12 million people will be affected by AF
by 2050 (Shafeeq & Tran, 2014). In fact, AF will affect one in four people at some point during
their lifetime (Mahtani et al., 2012).
AF is concerning because it can lead to multiple complications. One of the most
devastating complications is ischemic stroke. Ischemic stroke due to AF can occur in all
populations, but it is most common in the elderly. People who are in their eighties have a 23.5%
risk for an ischemic stroke compared to a 1.5% risk in those who are in their fifties (Staerk,
Sherer, Ko, Benjamin, & Helm, 2017). The purpose of this paper is to review the
pathophysiology, clinical presentation, diagnosis of AF, and compare and contrast the use
of warfarin and the new oral anticoagulants (NOACs) for the prevention of ischemic
stroke in these patients.
Pathophysiology of Atrial Fibrillation and Ischemic Stroke
AF occurs when the normal sinoatrial node in the heart’s conduction is overridden by
high-frequency electrical impulses outside the sinoatrial node. This alteration in conduction
leads to dyssynchronous atrial contraction and an irregular ventricular conduction (Staerk et al.,
2017). This ineffective atrial contraction leads to the pooling of blood within the chamber and
possible formation of blood clots. When these clots are ejected, they risk being lodged within
the vessels of the brain leading to ischemic stroke.
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Clinical Presentation of Atrial Fibrillation
Risk Factors
Certain risk factors can make patients more prone to developing AF in their lifetime.
Non-modifiable risk factors for AF include a person’s age, sex, race, and genetic makeup. The
modifiable risk factors for AF include decreased physical activity, smoking, obesity, diabetes,
obstructive sleep apnea (OSA), and hypertension (Staerk et al., 2017).
Past Medical History
A past medical history of heart failure or myocardial infarction may put a patient at
greater risk for developing AF (Staerk et al., 2017). A first-degree relative with AF puts a person
at a 40% increased risk of having AF (Staerk et al., 2017).
Physical Exam Findings
When performing a physical examination, a nurse practitioner may palpate an irregular
pulse or auscultate an irregular heart rate. These assessment findings may prompt the nurse
practitioner to consider AF as a differential diagnosis.
Diagnosis
The diagnosis of AF is made by an electrocardiogram (ECG). The ECG will have a
characteristic wavy baseline with the absence of distinct P-waves. The QRS complexes will also
be irregular. The heart rate may vary, but is often greater than 100 beats per minute.
When a patient is diagnosed with AF, a complete workup should follow in an attempt to
determine the underlying cause. This workup may include an evaluation of serum cardiac
biomarkers and B-type natriuretic peptide (BNP) to investigate for underlying heart failure.
Chest radiography, thyroid function tests, complete blood cell (CBC) count, and serum
chemistries may also be helpful in determining the underlying cause (Staerk et al., 2017).
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Determining Risk of Complications
Unfortunately, it is not always possible to determine the cause of AF, which will require
the nurse practitioner to change the focus of care to the prevention of complications. One
potentially devastating complication is an ischemic stroke. A useful tool to determine the risk of
having a thromboembolic event or possible ischemic stroke is the CHADS2 score (Table 1). The
higher the score, the higher the risk for stroke.
Anticoagulation for the Prevention of Ischemic Stroke
Anticoagulation should be considered if the CHADS2 score is greater than or equal to one
(Zirlik & Bode, 2016). Up to 40% of eligible patients are not getting proper anticoagulation,
which places them at considerable risk for an ischemic stroke (Zirlik & Bode, 2016).
Anticoagulation
Warfarin has been used since 1954 and has been the mainstream anticoagulant used to
prevent clot formation and subsequent ischemic strokes (Bruins, Slot, & Berge, 2013).
Newer anticoagulants include apixaban, dabigatran, rivaroxaban, and edoxaban and are referred
to as NOACs. They have proven to lessen clot formation in the presence of AF and may be
considered alternatives to warfarin (Lip et al., 2018). Patients with heart valve problems, heart
valve replacement, or end-stage renal disease must be on warfarin since no other anticoagulant is
currently approved for their treatment (Shafeeq & Tran, 2014).
Effects on Clotting Cascade
Each anticoagulant affects a portion of the clotting cascade (Figure 1). Warfarin acts as a
vitamin K antagonist, blocking multiple areas within the clotting cascade. Dabigatran is a direct
thrombin inhibitor and blocks the final step in the coagulation cascade where fibrinogen is
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converted to fibrin (Salazar, del Aguila, & Cordova, 2016). Apixaban, rivaroxaban,
and edoxaban are all factor Xa inhibitors (Rogers & Finks, 2018).
Monitoring
Warfarin requires continued monitoring of the International Normalized Ratio (INR) to
ensure proper dosing. On the other hand, the NOACs are very predictive and constant in their
effects and do not require routine laboratory monitoring. Their therapeutic window and index do
not vary.
However, there may be times when laboratory monitoring of NOACs may be helpful or
required. These include suspected bleeding, recent significant trauma, or upcoming surgery.
When these needs occur, laboratory tests are available to check the patient’s anticoagulation
status (Table 3).
Diet Restrictions
It has long been known the effects of warfarin are limited by green leafy vegetables,
multivitamins, some enteral feeding formulas, grapefruit juice, and alcohol (Kampouraki &
Kamali, 2017). In comparison, the NOACs have no known dietary interaction (Mekaj, Mekaj,
Duci, & Miftari, 2015).
Medication Interactions
Warfarin interacts with CYP1A2, CYP2A6, CYP2C8, CYP2C9, and
CYP3A4 substrates (Garton, Dudzinski, & Kowey, 2014). Dabigatran, edoxaban, apixaban, and
rivaroxaban are contraindicated if taking defibrotide or mifepristone. Apixaban and rivaroxaban
are also contraindicated with a combined P-glycoprotein and a strong CYP3A4 inducer or
inhibitor (Garton, Dudzinski, & Kowey, 2014). Examples of these medications include
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antineoplastic drugs, calcium channel blockers, amiodarone, calcineurin inhibitors, digoxin,
macrolide antibiotics, and protease inhibitor (Garton, Dudzinski, & Kowey, 2014).
Dabigatran has also been shown to increase the risk of severe hemorrhage when
taken with ketoconazole, amiodarone, verapamil, ticagrelor, and clarithromycin (Finch & Pillans,
2014). For this reason, a careful medication history should be completed prior to beginning
warfarin or a NOAC.
Reversal Agents
Reversal agents may be required when taking an anticoagulant in the cases of severe
bleeding, major trauma, or in preparation for surgery. Fortunately, warfarin and most of the
NOACs have reversal agents, as shown in Tables 2 and 3 (Rogers & Finks, 2018). In cases of
severe bleeding, a patient would likely require blood transfusions while waiting for the reversal
agent to take effect. A patient on warfarin may require the administration of vitamin K and/or
fresh frozen plasma to reverse its effects (Griffiths et al., 2017).
Clinical trials are underway evaluating andexanet alfa as a reversal agent for edoxaban,
but it is not currently approved (Rogers & Finks, 2018). Having a reversal agent that is quick,
readily available, and reliable can be an important when considering options for anticoagulation.
Cost
The NOACs are all more expensive than warfarin when it comes to cost per pill (see
Table 3). However, warfarin does require lab draws to monitor the international normalized ratio
(INR) which need to be taken into consideration of overall costs. The INR test ranges from $6 to
$145 per lab draw (Chambers, Chadda, & Plumb, 2010).
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Although warfarin is the least expensive overall option, it is also the least convenient
with the need for follow up labs, potential medication interactions, and dietary restrictions. The
more expensive NOACs require no monitoring, so a patient is not burdened with lab draws.
Changing Anticoagulants
A patient may change from warfarin to a NOAC if there are medication interactions,
barriers to obtaining lab draws, or difficulty sustaining a therapeutic INR range. Patients also
may need to transition to warfarin if their kidney function worsens significantly or if they are no
longer able to afford a NOAC.
Case of Poor Renal Function
The NOACs are not Food and Drug Administration (FDA) approved for use in patients
currently on dialysis or in end-stage renal disease. Although not FDA approved, NOACs
continue to be prescribed for patients with poor renal function. When this is the case, apixaban
appears to be one of the safest options for those with chronic kidney disease. Apixaban has a
lower rate of stroke, death, and major bleeding compared to warfarin in patients with a
glomerular filtration rate of <50ml/min (Shamoun, Obeid, & Ramakrishna, 2015; Siontis et al.,
2018). One of the few advantages of warfarin over the NOACs is that warfarin can be used
without regard to renal function and can be used in dialysis patients as shown in Table 3.
Conclusion
If anticoagulation is indicated in AF, warfarin or a NOAC should be initiated to prevent
clots from forming and causing ischemic strokes. For the general population without valvular
disease or significant kidney disease, NOACs offer several advantages compared to warfarin.
Without routine monitoring and few interactions, NOACs simplify anticoagulation and often
provide better protection from ischemic stroke and other bleeding complications. If
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anticoagulation is recommended, the NOACs should be the preferred anticoagulants over
warfarin (Gambino, 2018). In cases of impaired renal function, excluding hemodialysis,
apixaban is the treatment of choice (Mekaj, Mekaj, Duci, & Miftari, 2015). Warfarin can be an
effective anticoagulant and currently is the only approved anticoagulant for patients on dialysis,
with a heart valve problem, or heart valve replacement (Mekaj, Mekaj, Duci, & Miftari, 2015).
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Table 1
CHADS2 Score
Category
C- Congestive heart failure
H- Hypertension
A- Age equal or over 75 years
D- Diabetes Mellitus
S- History of stroke or transient ischemic attack

11

Point value
1
1
1
1
2

Adapted from “Underuse of Anticoagulation in Older Patients with Atrial Fibrillation and
CHADS2 Score >2: Are We Doing Better Since the Marketing of Direct Oral Anticoagulants?”
by S. Henrard, C. Vandenabeele, S. Marien, B. Boland, and O. Dalleur, 2017, Drugs & Aging,
34, p. 841-850.

Table 2
NOACs Reversal Agents
NOAC
Reversal Agent
Apixaban
Adexanet Alpha
Dabigatran
Idarucizumab
Rivaroxaban
Adexanet Alpha
Edoxaban
Adexanet Alpha (in clinical trial)
(Rogers & Finks, 2018).

Time Required to Reverse Medication
3 hours
4 hours
3 hours
NA
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Table 3
Summary Table for Comparison of NOACs and Warfarin
Dabigatran (Pradaxa)
NOAC, direct thrombin
inhibitor
None
Activated partial
thromboplastin time
or Hemoclot assay

Food interaction

Apixaban (Eliquis)
NOAC, Factor Xa
inhibitor
None
Prothrombin time or
chromogenic antifactory
Xa assay (normal range
20-660ng/ml)
None

Contraindicated
Medication

Defibrotide and
Mifepristone.

Defibrotide and
Mifepristone.

Medication Class
Required Monitoring
Labs Used to Monitor

None

Rivaroxaban (Xarelto)
NOAC, Factor Xa inhibitor
None
Prothrombin time or
chromogenic antifactory Xa
assay (normal range 20660ng/ml)
None
Defibrotide and Mifepristone.

Edoxaban (Savaysa)
NOAC, Factor Xa
inhibitor
None
Chromogenic antifactory
Xa assay (normal range
20-660ng/ml)

Warfarin (Coumadin)
Vitamin K Antagonist

None

Foods with vitamin K, some
enteral feeds, grapefruit, alcohol
Interacts with CYP1A2, CYP2A6,
CYP2C8, CYP2C9, CYP3A4
substrates.

Defibrotide and
Mifepristone.

Interacts with the CYP3A4
substrate.

Interacts with the
CYP3A4 substrate.
Reversal agents

Andexanet alfa

Idarucizumab

Andexanet alfa

None

Cost average
(Good RX-as of April
2018)
Dosing
Renal function

$215/30 tabs

$194/30 tabs

$430/30 tabs

$350/30 tabs

1-2/day
CrCl>15 mL/min needed.
No dialysis.

2 times a day
Dose adjustment needed
with CrCl 15-30 mL/min.

1-2/ day
CrCl< 30 mL/min should
avoid.

One per day
Recommended CrCl>95
mL/min.

Not indicated CrCl < 15
mL/min.

No dialysis.

No dialysis.

INR
INR

Multi-vitamins containing Vitamin
K
Vitamin K and fresh frozen
plasma,.
$4-7/30 tabs plus lab draw fees

One per day
Used in all kidney functions.
Okay with dialysis.

No dialysis

(Rogers & Finks, 2018; Griffiths et al., 2017; May, 2018; Kampouraki & Kamlai, 2017; Mekaj et al., 2015; Garton, Dudzinski, & Kowey, 2014; Shamoun,
Obeid, & Ramakrishna, 2015; Siontis et al., 2018; Salazar, del Aguila, & Cordova, 2016; Shafeeq & Tran, 2014; Albert, 2014)
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Figure 1. Clotting Cascade
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Figure 1. Where the NOACs and warfarin affect the clotting cascade. Adapted from “New Oral
Anticoagulants: Their Advantages and Disadvantages Compared with Vitamin K Antagonists in
the Prevention and Treatment of Patients with Thromboembolic Events,” by Y. H. Mekaj, A. Y.
Mekaj, S. B. Duci, and E. I. Miftari, 2015, Therapeutics and Clinical Risk Management, 2015, p.
967-977.

